medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2015, Number 3

<< Back Next >>

Ann Hepatol 2015; 14 (3)

Obesity as a cause of hepatocellular carcinoma

Kew MC

Language: English
References: 46
Page: 299-303
PDF size: 72.32 Kb.


ABSTRACT

During recent years the incidence of obesity has increased significantly, and in some instances rapidly, in many resource-rich countries. Paralleling this increase has been an increase in the incidence of hepatocellular carcinoma. It has been estimated that as many as 90% of obese adults will develop the metabolic syndrome. The worldwide incidence of this syndrome in adults at this time ranges from 9 to 34%. Furthermore, obesity in childhood increases the risk of obesity in adulthood, and hence the development of the metabolic syndrome and hepatocellular carcinoma. Ten to 20% of patients with non-alcoholic fatty liver disease progress to non-alcoholic steatohepatitis, and 8.3% of the latter develop cirrhosis. Up to 50% of these patients with cirrhosis, and a significant proportion of those without cirrhosis, progress to hepatocellular carcinoma. Much remains to be learnt about the mechanisms by which obesity and the metabolic syndrome cause hepatocellular carcinoma, although insulin resistance, increased tissue necrosis factor activity, alterations in serum lipids, non-alcoholic fatty liver disease and non-alcoholic steatosis play important roles. There is also increasing evidence that gut microbiota play a role in the development of the metabolic syndrome and hence of hepatocellular carcinoma.


REFERENCES

  1. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365: 1118-27.

  2. Larsson SC, Wolk A. Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer 2007; 97: 1005-08.

  3. Schlesinger S, Alecksandrova K, Pischon T, Ferdiko V, Jenab M, Trepo C, Boffetta P, et al. Abdominal obesity, weight gain during adulthood and risk of liver and biliary tract cancer in a European cohort. Int J Cancer 2013; 132: 645-57.

  4. Moller H, Mellemgard A, Lindvig K, Olden JH. Obesity and cancer risk: a Danish record-linkage study. Eur J Cancer 1994; 30A: 344-50.

  5. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma: incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009; 27: 1485-91.

  6. Berentzen TL, Gamberg M, Holst C, Sorensen TI, Bakese JL. Body mass index in childhood and adult risk of primary liver cancer. J Hepatol 2013; 60: 325-30.

  7. Nobili V, Alisi A, Grimaldi C, Liccardo D, Francalanci P, Monti L, Castellano A, et al. Fatty liver disease and hepatocellular carcinoma in a 7-year-old obese boy: Co-incidence or co-morbidity? Pediat Obes 2013; epub ahead of print.

  8. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among United States adults. Findings of the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-9.

  9. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new worldwide definition. Consensus statement from the International Diabetes federation. Diabet Med 2006; 23: 469-80.

  10. Petta S, Craxi A. Hepatocellular carcinoma and non-alcoholic fatty liver disease: from a clinical to a molecular association. Curr Pharm Res 2010; 16: 741-52.

  11. Starley BQ, Calnogno CJ, Harrison SA. Non-alcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. J Hepatol 2010; 51: 1820-32.

  12. Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol 2012; 56: 1384-91.

  13. Siegel AB, Zhu AX. Metabolic syndrome and hepatocellular carcinoma. Cancer 2009; 115: 5651-61.

  14. Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. Hepatology 2010; 51: 1972-8.

  15. Borena W, Strohmaier S, Lukanova A, Biorgi T, Lindkwist A, Hallmans G, Edinger M, et al. Metabolic risk factors and primary liver cancer in a prospective study of 578,700 subjects. Int J Cancer 2012; 131: 193-2000.

  16. Rahman R, Hammoud GM, Almashhrawi AA, Ahmed KD, Ibdak JA.l. Primary hepatocellular carcinoma and the metabolic syndrome: An update. World J Gastrointest Oncology 2013; 5: 186-94.

  17. Welzel TM, Graubard BI, Zeuzem S, Davila A, McGlynn KA, El-Serag HB. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare data base. Hepatology 2011; 54: 463-71.

  18. Borch-Johnson K. The metabolic syndrome in a global perspective. The public health impact-secondary publication. Dan Med Bull 2007; 54: 157-9.

  19. Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Fyjii K, Omatsu T, Nakajima T, et al. The metabolic syndrome as a predictor of non-alcoholic fatty liver disease. Ann Intern Med 2005; 143: 722-8.

  20. Ervin RB. Prevalence of metabolic syndrome among adults 20 years and older by sex, age, race, ethnicity and body mass index: United States 2003-2006. Natl Health Stat Report 2009; 13: 1-7.

  21. Caldwell S, Argo C. The natural history of non-alcoholic fatty liver disease. Dig Dis Sci 2010; 28: 162-8.

  22. Angulo P. Non-alcoholic liver disease. N Engl J Med 2002; 346: 1221-31.

  23. Matteoni CA, Younossis ZM, Gramlich T, et al. Non-alcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-9.

  24. Marcheseni G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianisi E, McCullough AJ, Farlani G, et al. Association of non-alcoholic fatty liver disease with insulin resistance. Amer J Med 1999; 107: 450-5.

  25. Lazo M, Clark JM. The epidemiology of non-alcoholic fatty liver disease: a global perspective. Sem Liv Dis 2008; 28: 339-50.

  26. Adams LA, Lymp JF, St Stauer J, Sanderson SP, Lindor KD, Feldstein A, Angulo P, et al. The natural history of non-alcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113-21.

  27. Paradis V, Zalinski S, Chelbi E, Guedj N, Gegos F, Vilgrain V, Bedossa P, et al. Hepatocellular carcinoma in patients with metabolic syndrome often develop without significant fibrosis: a pathological analysis. Hepatology 2009; 49: 851-9.

  28. Duan XY, Qia L, Fan FG. Clinical features of NAFL-induced hepatocellular carcinoma. Hepatobil Pancreat Dis Int 2012; 11: 18-27.

  29. Yasui K, Hashimoto E, Komorizono Y, Koike K, Avii SS, Imai Y, Shuma T, et al. Characteristics of patients with non-alcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol 2011; 9: 428-33.

  30. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gastur SM, Habel LA, Pollack M. Diabetes and cancer: a consensus report. Diabet Care 2010; 33: 1674-85.

  31. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population-based case control study. Gut 2005; 54: 533-9.

  32. Ertle J, Dechene A, Sowa JP, Penndorf V, Herzer K, Kaiser G, Schlaak JF, et al. Non-alcoholic fatty liver disease 303 Obesity as a cause of hepatocellular carcinoma. , 2015; 14 (3): 209-303 progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer 2011; 128: 2436-43.

  33. El-Serag HB, Hampel R, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. J Clin Gastronterol Hepatol 2006; 4: 369-80.

  34. Byrne CD. Ectopic fat, insulin resistance and non-alcoholic fatty liver disease. Proc Nutr Soc 2013; 72: 412-9.

  35. Rosmarduc O. Relation between hepatocellular carcinoma, metabolic syndrome and non-alcoholic fatty liver disease: which clinical arguments? Ann Endocrin (Paris) 2013; 74: 115-20.

  36. Siddeque A, Kowdley KV. Insulin resistance and other metabolic risk factors in the pathogenesis of hepatocellular carcinoma. Clin Liv Dis 2011; 15: 286-96.

  37. Ikeda Y, Kajiyama K, Yamesheta Y, Ikegami T, Uchiyama H, Soejima Y, Kawanaka H, et al. Differential expression of insulin-like growth factor 1 in primary liver cancer. Fukuoka Igaku Zasshi 2013; 104: 334-8.

  38. Ye D, Li F, Lam KF, Jia W, Li H, Jia W, Wang Y, et al. Tolllike receptor-4 mediates obesity-induced non-alcoholic steatohepatitis through activation of X-box binding protein in mice. Gut 2012; 6: 1058-67.

  39. Mansour M. T the roles of perioxisome proliferator receptors in the metabolic syndrome. Prog Mol Biol Transl Sci 2014; 121: 217-66.

  40. El-Kadre LJ, Tinoco AC. Interleukin-6 and obesity: crosstalk between intestine, pancreas and liver. Curr Opin Clin Nutr Metab Care 2013; 16: 564-8.

  41. ParK EJ, Lee JH, Yu Gy, He G, Ali SR, Holzer RG, Osterr CH, et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010; 140: 197-208.

  42. Liedtke C, Plumpe J, Kubicke S, Bradham GA, Manns MP, Brenue DA, Trautwein C. Jun kinase modulates tumor necrosis factor-depedent apoptosis in liver cells. Hepatology 2002; 36: 315-25.

  43. Procacini C, Gaklgami M, De Rosa V, Carbone F, La Rocci, Ranucci G, Matarese G, et al. Leptin, the prototype adipocytokine and its role in NAFLD. Curr Pharm Des 2010; 16: 1913-20.

  44. Singh DK, Sekiya P, Restogi A, Singh A, Gondal R, Sarin K. Serum leptin levels correlate with body mass index but not with histologic disease severity in Indian patients with NASH: A pilot study. Ind J Med Res 2013; 137: 986-7.

  45. Chassaing B, Etienne-Mesmin L, Gewertz AT. Microbiotaliver axis in hepatic disease. Hepatology 2014; 59: 328-39.

  46. Gomez-Hurtado Santacuz A, Peiro G, Zapater Z, et al. Gut translocation in mice with ccl4-induced fibrosis. PloS ONE 2011; 6: e23037.




2020     |     www.medigraphic.com